Viral Infections
RSSArticles
-
COVID-19 Pre-Exposure Prophylaxis
The combination of tixagevimab and cilgavimab (Evusheld) was demonstrated to be effective in the prevention of symptomatic COVID-19, but much remains to be learned as SARS-CoV-2 continues to evolve.
-
Who Can Get the Janssen/J&J (Non-mRNA) COVID-19 Vaccine Now?
The Food and Drug Administration recently limited the use of the Janssen COVID-19 vaccine.
-
Pregnant, Influenza-Infected, and Hospitalized
Almost one-third of women age 15-44 years hospitalized with influenza were pregnant and almost 5% required intensive care.
-
Outcomes of COVID-19-Associated Acute Myocarditis
In a review of COVID-19-associated acute myocarditis, investigators learned it is a rare complication that can occur without concomitant pneumonia, and frequently presents as cardiogenic shock. With supportive therapy, the short-term mortality rate is low.
-
COVID-19 Vaccine and the Menstrual Cycle
In a retrospective cohort analysis of prospectively tracked menstrual cycle data from the smartphone application “Natural Cycles,” the COVID-19 vaccine was associated with a less than one day change in menstrual cycle length and no change in menses length.
-
Infectious Disease Alert Updates
Recovering from Critical COVID; Oral and Anal Transmission of Syphilis
-
A Case of Monkeypox in a Returned Traveler
The arrival of a traveler from Nigeria to the United States with monkeypox infection, which was quickly recognized, led to a massive public health response investigating exposed individuals, but no secondary cases were detected.
-
Maribavir (Livtencity)
The FDA approved maribavir as the first drug to treat adult and pediatric patients with post-transplant cytomegalovirus infections that do not respond to currently available antiviral treatment.
-
Persistent Inflammation and Post-COVID Syndrome
Ongoing inflammation may contribute to long COVID.
-
Bloodstream Infections During COVID-19
Severity of illness, prolonged hospital stays, use of mechanical ventilation, and use of immune-modulating agents in patients with COVID-19 may have contributed to observed increases in hospital-acquired blood stream infections and attendant mortality.